BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

...numbers of patients. For an MPS-I patient who weighed 25 kg, BioMarin Pharmaceutical Inc.’s Aldurazyme laronidase...
...As CMO of rare disease company BioMarin during 1998-2009, he led development and commercialization of Aldurazyme...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

...health, Goldberg helped develop and get approved Fabrazyme agalsidase beta to treat Fabry's disease, Aldurazyme laronidase...
BioCentury | Dec 8, 2014
Strategy

BioMarin bulks up

...example, he cited BioMarin's first product, Aldurazyme laronidase. In 2003, FDA granted full approval to Aldurazyme...
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...gene therapy to treat MPS I. BioMarin Pharmaceutical Inc. and Sanofi market recombinant IDUA Aldurazyme laronidase...
BioCentury | Sep 18, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...therapy to treat MPS I. BioMarin Pharmaceutical Inc. and Sanofi market the recombinant IDUA Aldurazyme laronidase...
BioCentury | Jun 16, 2014
Regulation

Signal crossing

...Leigh disease. Enzyme replacement therapies are available for some of the disorders, such as Aldurazyme laronidase...
...galsulfase to treat MPS-VI. BioMarin Pharmaceutical Inc. markets Kuvan , Naglazyme and Vimizim, and markets Aldurazyme...
BioCentury | Mar 31, 2014
Regulation

Viral crossroads

...one example where a death in an expanded access program did not prevent approval: Aldurazyme laronidase...
...by BioMarin Pharmaceutical Inc. and partner Genzyme Corp. for a January 2003 advisory committee meeting, Aldurazyme...
...trials. A 10-year-old patient who was treated under a single-patient special access protocol died. "With Aldurazyme...
BioCentury | Feb 20, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...gene therapy in mouse models of other types of MPS. BioMarin Pharmaceutical Inc. markets Aldurazyme laronidase...
BioCentury | Jan 28, 2013
Tools & Techniques

BioMarin's brainy buy

...enzymes and small molecules discovered via Zacharon's platform. BioMarin markets two mucopolysaccharidosis products - Aldurazyme laronidase...
BioCentury | Nov 5, 2012
Strategy

Orphanage in Asia

...Orphan drugs in Japan. These include three of its own drugs and MPS-I product Aldurazyme laronidase...
Items per page:
1 - 10 of 171